These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16973133)

  • 1. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
    Olivier S; Robe P; Bours V
    Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
    Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation.
    Tse AK; Wan CK; Zhu GY; Shen XL; Cheung HY; Yang M; Fong WF
    Mol Immunol; 2007 Apr; 44(10):2647-58. PubMed ID: 17240450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome--an emerging therapeutic target in cancer.
    Mitchell BS
    N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
    [No Abstract]   [Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other compounds and targets in non-small cell lung cancer.
    Villaflor V; Bonomi P
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S30-6. PubMed ID: 16459177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.
    McCarty MF; Block KI
    Integr Cancer Ther; 2006 Sep; 5(3):252-68. PubMed ID: 16880431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
    Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
    Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.